Study identification

EU PAS number

EUPAS1000000752

Study ID

1000000752

Official title and acronym

CABOLIFE: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients with Neuroendocrine Tumours

DARWIN EU® study

No

Study countries

Austria
Germany

Study description

This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants’ quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.

Study status

Planned

Contact details

Ipsen Medical Director

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 
Regulatory

Was the study required by a regulatory body?

Unknown

Is the study required by a Risk Management Plan (RMP)?

Not applicable